Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 24;11:10765. doi: 10.1038/s41598-021-90143-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Mice bearing 22Rv1 prostate cancer xenografts were treated with abiraterone acetate (AA) at 5 mmol/kg/day or vehicle control (95% safflower oil, 5% benzyl alcohol) via intraperitoneal injection every day for either (a) 5 or (b) 15 days. RNA was extracted from harvested tumor or liver tissue and reverse transcribed for analysis by qPCR. Gene expression was normalized to expression of β-actin. Significant upregulation of SLCO1B3 was observed at both time points. Mouse livers were assessed for changes in slco1b2 (the mouse analogue of human SLCO1B3) expression. While AA treatment induced a statistically significant decrease in mouse liver slco1b2 expression, the magnitude of the change was small and may not reflect how SLCO1B3 expression in a human liver would be affected by AA treatment. *P < 0.05.